ClinicalTrials.gg
RecruitingNCT04566991DISHUpdated Nov 12, 2026

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

A Phase 2 interventional study of Deferoxamine and Placebo in Aneurysmal Subarachnoid Hemorrhage, sponsored by Aditya S. Pandey, MD. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Aditya S. Pandey, MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Subarachnoid Hemorrhage with a site in United States — 31 open to participants now, 37 under way, 2 of them phase 3. Subarachnoid Hemorrhage · United States.

Planned enrollment
19th of 107
120 · median 30
Started
2022
with 2 others
Phase 2
18 of 149
4 open now
Primary completion
2029-10
later than 34 of 36 live
Registered
114th of 149
by date

Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, this one is the 19th largest by planned enrollment of the 107 interventional ones that give a count, is one of 3 that started in 2022, is one of 18 in phase 2, reaches primary completion later than 34 of the 36 other live ones, and was the 114th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

31 of the 149 studies in Subarachnoid Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Subarachnoid Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals.

This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.

03

Conditions studied

  • Aneurysmal Subarachnoid Hemorrhage

Keywords

  • Deferoxamine
  • Placebo
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aneurysmal SAH confirmed with vascular imaging
  • Aneurysm treated with endovascular or microsurgical intervention
  • Hunt-Hess ≤ 4
  • Modified Fisher Grade I-IV
  • Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated
  • First dose of drug can be administered within 24 hours of symptom onset
  • Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1
  • obtained by patient or legal authorized representative (LAR)

Exclusion criteria

Exclusion Criteria:

  • Previous to or treatment with deferoxamine
  • Presence of giant aneurysm (>25 mm in size)
  • Known severe iron deficiency anemia, (Hgb) g/dl ≤ 7 or transfusion dependent
  • Irreversibly impaired brainstem function
  • Abnormal renal function, Serum Creatinine> 2 mg/dL
  • Pre-existing severe disability, mRS ≥ 2
  • Coagulopathy, including use of anti- or anticoagulant drugs
  • Known severe hearing loss
  • Chronic pulmonary disease that limits basic activities of daily living at baseline, or requires the use of home oxygen.
  • Acute pulmonary disease with the need for any of the following - in a 72 hour period prior to enrollment: >4L/minute nasal cannula (or equivalent O2 delivery via face mask/ tent), heated-high flow nasal cannula, noninvasive positive pressure ventilation, and in intubated patients FiO2>45% or positive end-expiratory pressure (PEEP) > 8cmH2O. This does not include the use of supplemental oxygen in any form for pre-oxygenation, apneic oxygenation, or peri-procedural support alone.
  • Taking iron supplements containing > 325 mg of ferrous iron
  • Pregnancy or nursing
  • less than 90 days due to co-morbidities
  • Concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed
  • Prior history of hepatic dysfunction
  • Known cytopenia (platelets \< 50,000, \< 500)
  • Current use of prochlorperazine
  • History of severe psychiatric disorder
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Deferoxamine lower dose

    Deferoxamine 32 Milligram Per Kilogram (mg/kg)

    Drug: Deferoxamine

  • Experimental
    Deferoxamine higher dose

    Deferoxamine 48 mg/kg

    Drug: Deferoxamine

  • Placebo comparator
    Placebo

    normal saline

    Drug: Placebo

Interventions

  • There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose. Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.

    Also known as: Desferal

  • DrugPlacebo

    There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. Utility-weighted modified Rankin Scale (UW-mRS) at 6 months

    Overall a Bayesian, longitudinal model will be used, this will be adjusted for baseline expected 6 month mRS using the FRESH score. At baseline, the expected 6 month UW-mRS (based on prognostic variables such as age and Hunt Hess) will be entered as the first value for the patient. Therefore, patients with greater severity at baseline, who achieve excellent outcomes will contribute a larger treatment effect. Similarly, patients with greater severity who have disability, but perform better than expected can still contribute useful information.

    Time frame: 6 months (after hospital discharge)

Secondary outcomes

  1. Montreal Cognitive Assessment (MOCA)

    Montreal cognitive assessment is a rapid sensitive screening tool for assessment of impaired cognitive function. The main domains of MoCA scale include attention, executive functions, memory, language, attention, naming, orientation, and visual-spatial ability. The total score is 30 points. A score of 25 points or less indicated impaired cognitive function. For patients with less than 12 years of education, one point was added to the total score.

    Time frame: At discharge from hospital (approximately 3-4 weeks)

  2. Montreal Cognitive Assessment (MOCA)

    Montreal cognitive assessment is a rapid sensitive screening tool for assessment of impaired cognitive function. The main domains of MoCA scale include attention, executive functions, memory, language, attention, naming, orientation, and visual-spatial ability. The total score is 30 points. A score of 25 points or less indicated impaired cognitive function. For patients with less than 12 years of education, one point was added to the total score.

    Time frame: 6 months (after hospital discharge)

  3. Percentage of patients requiring permanent cerebrospinal fluid (CSF) diversion due to hydrocephalus at 6 months

    Time frame: 6 months

  4. Partial pressure of oxygen (PaO2) and fraction of inspired oxygen (FiO2) ratio (worst value for each parameter for each day of infusion, and 48 hours after end of infusion)

    Worst value for each parameter for each day of infusion, and 48 hours after end of infusion.

    Time frame: up to 48 hours after day 3 infusion

  5. To estimate the proportion of non-intubated participants at each dose who experience intubation or initiation of non-invasive positive pressure ventilation during the DFO

    Time frame: infusion days 1-3

  6. Incidence of delayed cerebral ischemia/vasospasm

    This is based on radiographic evidence on computed tomography angiogram and clinical correlation with neurologic exam.

    Time frame: up to 14 days after aSAH

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2022 (actual). Primary completion is estimated for Oct 2029, 91 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2027 → Oct 2029 and completion Oct 2027 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Sep 28, 2020
StartActual
Mar 20, 2022
Primary completionEst.
Oct 2029was Oct 2027
CompletionEst.
Oct 2029was Oct 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2027→Oct 2029
Nov 12, 2026
Study completion
Oct 2027→Oct 2029
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 2027→Oct 2029
    Study completion Oct 2027→Oct 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04566991
Lead sponsor
Aditya S. Pandey, MD
Responsible party
Aditya S. Pandey, MD (Associate Professor of Neurosurgery and Associate Professor of Radiology, University of Michigan) — Sponsor-investigator
First posted
Sep 28, 2020
Start date
Mar 20, 2022
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Sravanthi Koduri
Contact
skoduri@med.umich.edu
734-647-7960
Aditya Pandey, MD
Contact
adityap@umich.edu
734-615-2763
Aditya Pandey, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deferoxamine

Start the discussion